Is it the time of seno-therapeutics application in cardiovascular pathological conditions related to ageing?

Research output: Contribution to journalArticlepeer-review


It rates that in 2030, the cardiovascular diseases (CVD) will result in 40% of all deaths and rank as the leadingcause. Thus, the research of appropriate therapies able to delay or retard their onset and progression is growing.Of particular interest is a new branch of the medical science, called anti-ageing medicine since CVD are the result ofcardiovascular ageing. Senescent cells (SC) accumulate in cardiovascular system contributing to the onset oftypical age-related cardiovascular conditions (i.e., atherosclerosis, medial aorta degeneration, vascular remodeling,stiffness). Such conditions progress in cardiovascular pathologies (i.e., heart failure, coronary artery disease,myocardial infarction, and aneurysms) by evocating the production of a proinflammatory and profibroticsenescence-associated secretory phenotype (SASP). Consequently, therapies able to specifically eliminate SC arein developing. The senotherapeutics represents an emerging anti-SC treatment, and comprises three therapeuticapproaches: (a) molecules to selectively kill SC, defined senolytics; (b) compounds able in reducing evocated SCSASP, acting hence as SASP suppressors, or capable to change the senescent phenotype, called senomorphics; (c)inhibition of increase of the number of SC in the tissues. Here, it describes them and the emerging data aboutcurrent investigations on their potential clinical application in CVD, stressing benefits and limitations, and suggestingpotential solutions for applying them in near future as effective anti-CVD treatments
Original languageEnglish
Pages (from-to)100027-100032
Number of pages6
Publication statusPublished - 2021


Dive into the research topics of 'Is it the time of seno-therapeutics application in cardiovascular pathological conditions related to ageing?'. Together they form a unique fingerprint.

Cite this